$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
格列卫是什么公司产的?
2025-10-19 11:44:20
Check Details
利妥昔单抗的功效怎么样
2025-10-19 11:44:20
Check Details
利妥昔单抗的价格
2025-10-19 11:44:20
Check Details
格列卫医保价格
2025-10-19 11:44:20
Check Details
利妥昔单抗的详细说明书
2025-10-19 11:44:20
Check Details
格列卫上市价格
2025-10-19 11:44:20
Check Details
利妥昔单抗的最新价格
2025-10-19 11:44:20
Check Details
服用格列卫的注意事项
2025-10-19 11:44:20
Check Details
格列卫用法与用量
2025-10-19 11:44:20
Check Details
格列卫吃了能活多少年?
2025-10-19 11:44:20
Check Details
格列卫一盒多少钱?
2025-10-19 11:44:20
Check Details
格列卫中国上市价格
2025-10-19 11:44:20
Check Details
1
2
...
450
451
452
453
454
455
456
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ibrutinib for Mantle Cell Lymphoma: BTK Mechanism, Response Is Not Cure, Post-Resistance Options
2
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
3
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
4
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
5
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
6
First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20
7
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
8
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
9
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
10
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
11
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
12
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy